Perspectives on a Way Forward to Implementation of Precision Medicine in Patients With Diabetic Kidney Disease; Results of a Stakeholder Consensus-Building Meeting
Aim: This study aimed to identify from different stakeholders the benefits and obstacles of implementing precision medicine in diabetic kidney disease (DKD) and to build consensus about a way forward in order to treat, prevent, or even reverse this disease.Methods: As part of an ongoing effort of mo...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-05-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.662642/full |
| _version_ | 1818599581804396544 |
|---|---|
| author | Elisabeth Bakker Peter G. M. Mol Peter G. M. Mol Peter G. M. Mol João Nabais João Nabais Thorsten Vetter Matthias Kretzler John J. Nolan Gert Mayer Anna K. Sundgren Hiddo J. L. Heerspink Anja Schiel Anja Schiel Sieta T. de Vries Maria F. Gomez Friedrich Schulze Dick de Zeeuw Michelle J. Pena for the BEAt-DKD Consortium |
| author_facet | Elisabeth Bakker Peter G. M. Mol Peter G. M. Mol Peter G. M. Mol João Nabais João Nabais Thorsten Vetter Matthias Kretzler John J. Nolan Gert Mayer Anna K. Sundgren Hiddo J. L. Heerspink Anja Schiel Anja Schiel Sieta T. de Vries Maria F. Gomez Friedrich Schulze Dick de Zeeuw Michelle J. Pena for the BEAt-DKD Consortium |
| author_sort | Elisabeth Bakker |
| collection | DOAJ |
| description | Aim: This study aimed to identify from different stakeholders the benefits and obstacles of implementing precision medicine in diabetic kidney disease (DKD) and to build consensus about a way forward in order to treat, prevent, or even reverse this disease.Methods: As part of an ongoing effort of moving implementation of precision medicine in DKD forward, a two-day consensus-building meeting was organized with different stakeholders involved in drug development and patient care in DKD, including patients, patient representatives, pharmaceutical industry, regulatory agencies representatives, health technology assessors, healthcare professionals, basic scientists, and clinical academic researchers. The meeting consisted of plenary presentations and discussions, and small group break-out sessions. Discussion topics were based on a symposium, focus groups and literature search. Benefits, obstacles and potential solutions toward implementing precision medicine were discussed. Results from the break-out sessions were presented in plenary and formed the basis of a broad consensus discussion to reach final conclusions. Throughout the meeting, participants answered several statement and open-ended questions on their mobile device, using a real-time online survey tool. Answers to the statement questions were analyzed descriptively. Results of the open-ended survey questions, the break-out sessions and the consensus discussion were analyzed qualitatively.Results and conclusion: Seventy-one participants from 26 countries attended the consensus-building meeting in Amsterdam, April 2019. During the opening plenary on the first day, the participants agreed with the statement that precision medicine is the way forward in DKD (n = 57, median 90, IQR [75–100]). Lack of efficient tools for implementation in practice and generating robust data were identified as significant obstacles. The identified benefits, e.g., improvement of the benefit-risk ratio of treatment, offer substantive incentives to find solutions for the identified obstacles. Earlier and increased multi-stakeholder collaboration and specific training may provide solutions to alter clinical and regulatory guidelines that lie at the basis of both obstacles and solutions. At the end of the second day, the opinion of the participants toward precision medicine in DKD was somewhat more nuanced (n = 45, median 83, IQR [70–92]) and they concluded that precision medicine is an important way forward in improving the treatment of patients with DKD. |
| first_indexed | 2024-12-16T12:21:52Z |
| format | Article |
| id | doaj.art-f77b8bd284ea47e89bad5a6ed9657caf |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-16T12:21:52Z |
| publishDate | 2021-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-f77b8bd284ea47e89bad5a6ed9657caf2022-12-21T22:31:56ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122021-05-011210.3389/fphar.2021.662642662642Perspectives on a Way Forward to Implementation of Precision Medicine in Patients With Diabetic Kidney Disease; Results of a Stakeholder Consensus-Building MeetingElisabeth Bakker0Peter G. M. Mol1Peter G. M. Mol2Peter G. M. Mol3João Nabais4João Nabais5Thorsten Vetter6Matthias Kretzler7John J. Nolan8Gert Mayer9Anna K. Sundgren10Hiddo J. L. Heerspink11Anja Schiel12Anja Schiel13Sieta T. de Vries14Maria F. Gomez15Friedrich Schulze16Dick de Zeeuw17Michelle J. Pena18for the BEAt-DKD ConsortiumDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, NetherlandsDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, NetherlandsDutch Medicines Evaluation Board (CBG-MEB), Utrecht, NetherlandsScientific Advice Working Party, European Medicines Agency (EMA), Amsterdam, NetherlandsAssociação Protetora Dos Diabéticos de Portugal, Lisboa, PortugalComprehensive Health Reserach Centre (CHRC), Departamento de Ciências Médicas e da Saúde, Escola de Saúde e Desenvolvimento Humano, Universidade de Évora, Évora, PortugalEuropean Medicines Agency (EMA), Amsterdam, NetherlandsUniversity of Michigan, Michigan Medicine, Internal Medicine/Nephrology and Computational Medicine and Bioinformatics, Ann Arbor, MI, United StatesUniversity of Dublin, Trinity College, Dublin, IrelandDepartment of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, Innsbruck, Austria0AstraZeneca, Gaithersburg, MD, United StatesDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, NetherlandsScientific Advice Working Party, European Medicines Agency (EMA), Amsterdam, Netherlands1Norwegian Medicines Agency, Oslo, NorwayDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands2Department of Clinical Sciences, Lund University, Diabetes Centre, Malmö, Sweden3Boehringer Ingelheim International GmbH, Ingelheim, GermanyDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, NetherlandsDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, NetherlandsAim: This study aimed to identify from different stakeholders the benefits and obstacles of implementing precision medicine in diabetic kidney disease (DKD) and to build consensus about a way forward in order to treat, prevent, or even reverse this disease.Methods: As part of an ongoing effort of moving implementation of precision medicine in DKD forward, a two-day consensus-building meeting was organized with different stakeholders involved in drug development and patient care in DKD, including patients, patient representatives, pharmaceutical industry, regulatory agencies representatives, health technology assessors, healthcare professionals, basic scientists, and clinical academic researchers. The meeting consisted of plenary presentations and discussions, and small group break-out sessions. Discussion topics were based on a symposium, focus groups and literature search. Benefits, obstacles and potential solutions toward implementing precision medicine were discussed. Results from the break-out sessions were presented in plenary and formed the basis of a broad consensus discussion to reach final conclusions. Throughout the meeting, participants answered several statement and open-ended questions on their mobile device, using a real-time online survey tool. Answers to the statement questions were analyzed descriptively. Results of the open-ended survey questions, the break-out sessions and the consensus discussion were analyzed qualitatively.Results and conclusion: Seventy-one participants from 26 countries attended the consensus-building meeting in Amsterdam, April 2019. During the opening plenary on the first day, the participants agreed with the statement that precision medicine is the way forward in DKD (n = 57, median 90, IQR [75–100]). Lack of efficient tools for implementation in practice and generating robust data were identified as significant obstacles. The identified benefits, e.g., improvement of the benefit-risk ratio of treatment, offer substantive incentives to find solutions for the identified obstacles. Earlier and increased multi-stakeholder collaboration and specific training may provide solutions to alter clinical and regulatory guidelines that lie at the basis of both obstacles and solutions. At the end of the second day, the opinion of the participants toward precision medicine in DKD was somewhat more nuanced (n = 45, median 83, IQR [70–92]) and they concluded that precision medicine is an important way forward in improving the treatment of patients with DKD.https://www.frontiersin.org/articles/10.3389/fphar.2021.662642/fullprecision medicinepersonalized medicineconsensus meetingdiabetic nephropathydiabetic kidney diseasestakeholder conference |
| spellingShingle | Elisabeth Bakker Peter G. M. Mol Peter G. M. Mol Peter G. M. Mol João Nabais João Nabais Thorsten Vetter Matthias Kretzler John J. Nolan Gert Mayer Anna K. Sundgren Hiddo J. L. Heerspink Anja Schiel Anja Schiel Sieta T. de Vries Maria F. Gomez Friedrich Schulze Dick de Zeeuw Michelle J. Pena for the BEAt-DKD Consortium Perspectives on a Way Forward to Implementation of Precision Medicine in Patients With Diabetic Kidney Disease; Results of a Stakeholder Consensus-Building Meeting Frontiers in Pharmacology precision medicine personalized medicine consensus meeting diabetic nephropathy diabetic kidney disease stakeholder conference |
| title | Perspectives on a Way Forward to Implementation of Precision Medicine in Patients With Diabetic Kidney Disease; Results of a Stakeholder Consensus-Building Meeting |
| title_full | Perspectives on a Way Forward to Implementation of Precision Medicine in Patients With Diabetic Kidney Disease; Results of a Stakeholder Consensus-Building Meeting |
| title_fullStr | Perspectives on a Way Forward to Implementation of Precision Medicine in Patients With Diabetic Kidney Disease; Results of a Stakeholder Consensus-Building Meeting |
| title_full_unstemmed | Perspectives on a Way Forward to Implementation of Precision Medicine in Patients With Diabetic Kidney Disease; Results of a Stakeholder Consensus-Building Meeting |
| title_short | Perspectives on a Way Forward to Implementation of Precision Medicine in Patients With Diabetic Kidney Disease; Results of a Stakeholder Consensus-Building Meeting |
| title_sort | perspectives on a way forward to implementation of precision medicine in patients with diabetic kidney disease results of a stakeholder consensus building meeting |
| topic | precision medicine personalized medicine consensus meeting diabetic nephropathy diabetic kidney disease stakeholder conference |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2021.662642/full |
| work_keys_str_mv | AT elisabethbakker perspectivesonawayforwardtoimplementationofprecisionmedicineinpatientswithdiabetickidneydiseaseresultsofastakeholderconsensusbuildingmeeting AT petergmmol perspectivesonawayforwardtoimplementationofprecisionmedicineinpatientswithdiabetickidneydiseaseresultsofastakeholderconsensusbuildingmeeting AT petergmmol perspectivesonawayforwardtoimplementationofprecisionmedicineinpatientswithdiabetickidneydiseaseresultsofastakeholderconsensusbuildingmeeting AT petergmmol perspectivesonawayforwardtoimplementationofprecisionmedicineinpatientswithdiabetickidneydiseaseresultsofastakeholderconsensusbuildingmeeting AT joaonabais perspectivesonawayforwardtoimplementationofprecisionmedicineinpatientswithdiabetickidneydiseaseresultsofastakeholderconsensusbuildingmeeting AT joaonabais perspectivesonawayforwardtoimplementationofprecisionmedicineinpatientswithdiabetickidneydiseaseresultsofastakeholderconsensusbuildingmeeting AT thorstenvetter perspectivesonawayforwardtoimplementationofprecisionmedicineinpatientswithdiabetickidneydiseaseresultsofastakeholderconsensusbuildingmeeting AT matthiaskretzler perspectivesonawayforwardtoimplementationofprecisionmedicineinpatientswithdiabetickidneydiseaseresultsofastakeholderconsensusbuildingmeeting AT johnjnolan perspectivesonawayforwardtoimplementationofprecisionmedicineinpatientswithdiabetickidneydiseaseresultsofastakeholderconsensusbuildingmeeting AT gertmayer perspectivesonawayforwardtoimplementationofprecisionmedicineinpatientswithdiabetickidneydiseaseresultsofastakeholderconsensusbuildingmeeting AT annaksundgren perspectivesonawayforwardtoimplementationofprecisionmedicineinpatientswithdiabetickidneydiseaseresultsofastakeholderconsensusbuildingmeeting AT hiddojlheerspink perspectivesonawayforwardtoimplementationofprecisionmedicineinpatientswithdiabetickidneydiseaseresultsofastakeholderconsensusbuildingmeeting AT anjaschiel perspectivesonawayforwardtoimplementationofprecisionmedicineinpatientswithdiabetickidneydiseaseresultsofastakeholderconsensusbuildingmeeting AT anjaschiel perspectivesonawayforwardtoimplementationofprecisionmedicineinpatientswithdiabetickidneydiseaseresultsofastakeholderconsensusbuildingmeeting AT sietatdevries perspectivesonawayforwardtoimplementationofprecisionmedicineinpatientswithdiabetickidneydiseaseresultsofastakeholderconsensusbuildingmeeting AT mariafgomez perspectivesonawayforwardtoimplementationofprecisionmedicineinpatientswithdiabetickidneydiseaseresultsofastakeholderconsensusbuildingmeeting AT friedrichschulze perspectivesonawayforwardtoimplementationofprecisionmedicineinpatientswithdiabetickidneydiseaseresultsofastakeholderconsensusbuildingmeeting AT dickdezeeuw perspectivesonawayforwardtoimplementationofprecisionmedicineinpatientswithdiabetickidneydiseaseresultsofastakeholderconsensusbuildingmeeting AT michellejpena perspectivesonawayforwardtoimplementationofprecisionmedicineinpatientswithdiabetickidneydiseaseresultsofastakeholderconsensusbuildingmeeting AT forthebeatdkdconsortium perspectivesonawayforwardtoimplementationofprecisionmedicineinpatientswithdiabetickidneydiseaseresultsofastakeholderconsensusbuildingmeeting |